Ramipril + Amlodipine + Atorvastatin [RAA]
Benefits at a glance
- Approved in EU
- Improving Patient´s adherence
- In accordance with latest scientific studies (START, SECURE)
5 mg + 5 mg + 20 mg
10 mg + 5 mg+ 20 mg
10 mg + 10 mg + 20 mg
10 mg + 10 mg + 40 mg
Atorvastatin Calcium Trihydrate
- Development Kick-off
- Formulation Development
- Pilot BE
- Scale Up
- Pivotal BE
- 6 M Stability
With our new fixed dose combination, we strive to treat two related cardiovascular diseases with one convenient tablet. Thereby we reduce the number of individual tablets the patient must take, while providing the required medication, leading to a long-term improvement in patient satisfaction through improved quality of life.
The treatment guidelines recommend the combination of Dyslipidemia and Hypertension medications, for the two related health conditions.
With approximately 40% of people above the age of 50 suffering from hypertension, this new fixed dose combination will be a patient friendly treatment option, that offers the possibility to unlock a large market potential.
Business Development & Licensing
The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.